Back to Search
Start Over
VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
- Source :
- Annals of Oncology. 33:112-113
- Publication Year :
- 2022
- Publisher :
- Elsevier BV, 2022.
Details
- ISSN :
- 09237534
- Volume :
- 33
- Database :
- OpenAIRE
- Journal :
- Annals of Oncology
- Accession number :
- edsair.doi...........60d3551b03e7599171f48ea844501b37
- Full Text :
- https://doi.org/10.1016/j.annonc.2021.10.007